Sector News

Chinese drugmakers, PE firms pile into Stada deal action

March 13, 2017
Life sciences

The race to snatch up generics maker Stada is heating up—and fast.

Just over two weeks after Boston private equity outfit Advent International put up the first legally binding bid for the drugmaker, multiple players are reportedly preparing to jump into the fray.

CVC Capital Partners, which held deal talks with Stada last year that would have helped the company dodge pressure from an activist shareholder, is ready to come back for another try, and it’s considering joining hands with a Chinese drugmaker to do it.

The private equity firm is in early-stage talks with Fosun Pharmaceuticals about a joint bid, Reuters reports, though Fosun—which is looking to continue down the global expansion path after acquiring India’s Gland Pharma last year—may instead decide to go solo on its Stada quest.

CVC is also talking with Shanghai Pharmaceuticals Holding about teaming up, Bloomberg says; sources tell the news service the companies will make a decision about pairing up as soon as next week.

For CVC, linking arms with a drugmaker could make a lot of sense. Pharma companies—unlike private equity groups—can squeeze costs out of an acquisition, so they can typically afford to bid higher.

That’s not to say private equity-only duos aren’t waiting in the wings, though. Advent may join forces with Permira, Bloomberg notes, and Singapore’s GIC is also interested in making an offer as an Advent coinvestor, the news service’s sources say. Bain Capital is in talks to join London’s Cinven, which has been in the mix from the start.

And it remains to be seen whether any drugmakers will show interest in Stada as a generics consolidation wave sweeps the industry. Analysts have floated Mylan as a good match, and StreetInsider reported on Thursday that Merck & Co. was working with Credit Suisse on an offer, though the New Jersey pharma giant doesn’t currently have any generics ops.

Whatever entrants do end up submitting bids for Stada will likely have to go past €3.6 billion if they want to come away victorious, Reuters points out. Confirmatory bids may match Advent’s at €58 per share, but sources expect that number to rise as high as €60.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach